Catheter-Directed Thrombolysis versus Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis

Link to article at PubMed

Curr Cardiol Rev. 2021 Jun 3. doi: 10.2174/1573403X17666210603114116. Online ahead of print.


BACKGROUND: The optimal therapy for submassive pulmonary embolism remains in question. The following meta-analysis compiles the current evidence comparing catheter-directed thrombolysis (CDT) versus systemic anticoagulation (SA).

METHODS: An electronic search through PubMed and Google scholar revealed studies comparing CDT versus SA in terms of mortality and major bleeding events. 30-day, 90-day, and 1-year mortality results were analyzed.

RESULTS: Six studies were included in the meta-analysis. Thirty-day and one-year mortality were less with CDT compared to SA (OR 0.27 [CI 0.11-0.67]; OR 0.50 [CI 0.28-0.89]). Ninety-day mortality was similar between the two methods (OR 0.57 [CI 0.17-1.92]). Compilation of all studies reporting at least greater than 30-day mortality revealed less mortality with CDT (OR 0.51 [0.30-0.86]). Major bleeding was similar between the two treatments (OR 1.63 [CI 0.63-4.20]).

CONCLUSION: CDT has less 30-day and 1-year mortality with equivalent rates of major bleeding compared to SA for treatment of submassive pulmonary embolism.

PMID:34082686 | DOI:10.2174/1573403X17666210603114116

Leave a Reply

Your email address will not be published.